// App-Quantinova.ai

9009 : Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Benjamin J. Solomon

Principal Investigators

  • Todd Michael Bauer

  • Enriqueta Felip

  • Benjamin Besse

  • Leonard Philip James

  • Jill S. Clancy

  • Karen J. Klamerus

  • Jean-Francois Martini

  • Antonello Abbattista

  • Alice Tsang Shaw

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Dpt of Medical Oncology, Gustave Roussy, Villejuif, France

  • Pfizer Inc, New York, NY

  • InVentiv Health, Princeton, NJ

  • Pfizer Inc, San Diego, CA

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, Milan, Italy

  • Massachusetts General Hospital, Boston, MA

Locations

  • Italy

  • Spain

  • Australia

  • United States

  • France

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Brain metastasis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

Drug/Treatment

  • Lorlatinib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT01970865

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved